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ABSTRACT
Introduction: The incidence of head and neck
cancer (HNC) in the UK is rising, with an average
of 31 people diagnosed daily. Patients affected by HNC
suffer significant short-term and long-term post-
treatment morbidity as a result of dysphagia, which
affects daily functioning and quality of life (QOL).
Pretreatment swallowing exercises may provide
additional benefit over standard rehabilitation in
managing dysphagia after primary HNC treatments, but
uncertainty about their effectiveness persists. This
study was preceded by an intervention development
phase to produce an optimised swallowing intervention
package (SIP). The aim of the current study is to
assess the feasibility of this new intervention and
research processes within a National Health Service
(NHS) setting.
Method and analysis: A two-arm non-blinded
randomised controlled feasibility study will be carried
out at one tertiary referral NHS centre providing
specialist services in HNC. Patients newly diagnosed
with stage III and IV disease undergoing planned
surgery and/or chemoradiation treatments will be
eligible. The SIP will be delivered pre treatment, and a
range of swallowing-related and QOL measures will be
collected at baseline, 1, 3 and 6 months post-
treatment. Outcomes will test the feasibility of a future
randomised controlled trial (RCT), detailing rate of
recruitment and patient acceptance to participation and
randomisation. Salient information relating to protocol
implementation will be collated and study material
such as the case report form will be tested. A range of
candidate outcome measures will be examined for
suitability in a larger RCT.
Ethics and dissemination: Ethical approval was
obtained from an NHS Research Ethics Committee.
Findings will be published open access in a peer-
reviewed journal, and presented at relevant conferences
and research meetings.
Trial registration number: ISRCTN40215425; Pre-
results.
INTRODUCTION
Background
Incidence of head and neck cancer (HNC) in
the UK is rising1 with an average of 31 people
receiving a new diagnosis daily.2 This increase
is primarily attributed to the rise in human
papilloma virus (HPV)-related oropharyngeal
cancer.3 Individuals with HPV-induced malig-
nancy are often much younger than those with
cancers induced by smoking and alcohol, and
often otherwise healthy and in active employ-
ment. Reducing the morbidity of cancer treat-
ments is a priority for the NHS Cancer Reform
Strategy4 and the Macmillan Living with and
Beyond Cancer Programme.5 Patients affected
by HNC suffer signiﬁcant short-term and long-
term post-treatment morbidity as a result of
dysphagia, which affects daily functioning and
quality of life (QOL). Swallowing difﬁculties
may arise secondary to the presence of
tumours in the mouth and throat, 6 from
damage or resection of swallowing-related soft
tissues and nerves during surgical interven-
tion7 and from the side effects and long-term
tissue damage following chemoradiation.8
Swallowing interventions that may ameliorate
Strengths and limitations of this study
▪ Use of a randomised controlled trial design to
minimise bias and differences between groups.
▪ Study design incorporates prior qualitative work
to optimise adherence to the intervention.
▪ Method includes consultation with clinicians
involved in usual care to devise a usual care
protocol to facilitate consistency.
▪ Limited to one hospital site.
▪ Patients and clinicians are not blinded to ran-
domisation allocation.
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the problems associated with eating and drinking after
primary HNC treatments (surgery, chemoradiotherapy)
are an important part of the care delivered to patients
diagnosed with HNC.9
Current UK practice for managing dysphagia in HNC
Traditionally, patients would have seen a speech and lan-
guage therapist (SLT) following their cancer treatment
for rehabilitation of their swallowing and communication
difﬁculties. A gradual shift in practice occurred following
publication of the National Institute for Health and Care
Excellence (NICE) Improving Outcomes Guidance,10
which recommend that patients should also see an SLT
prior to their treatment to inform them of the likely impact
to their swallowing and speech function. This information
giving is also viewed as a necessary part of the process of
informed consent. In support, an emerging number of
functional outcome studies have indicated that swallow
function pre treatment could be a strong predictor of
long-term swallow function post-treatment.11–13
Implementation of the NICE recommendation is cur-
rently variable. In some centres, patients are provided
with brief information by the SLT at the time of seeing
their medical consultant in a multidisciplinary clinic
setting. In other centres, separate SLT consultations take
place, which include documentation of baseline func-
tional measures for swallowing and communication, as
well as advice on diet modiﬁcation and the recommen-
dation to start a general protocol of swallowing exercises.
The latest report from the UK National Database of
Head and Neck Oncology (DAHNO)14 indicated that
only 29% of patients with HNC in England and Wales
were recorded as having a pretreatment SLT consult-
ation. Given the clinical and ﬁnancial resource implica-
tions of a separate pretreatment SLT consultation,
implementation will likely only increase if there is clear
speciﬁcation as to the optimal content of the consult-
ation, together with evidence supporting its beneﬁt on
patients’ outcomes. Aside from information giving, there
is a need to deﬁne what interventions administered
before treatment (prehabilitation) may improve patient
experience and/or post-treatment function.
The role and context of pretreatment swallowing exercises
The physiological rationale for prophylactic swallowing
exercises has been previously described in the literature.
Strength-based exercises and/or range of movement
exercises aimed at the swallowing musculature may
prevent muscle atrophy and reduce or delay the impact
of radiation-induced ﬁbrosis.15–18 Preconditioning
through exercises has been reported to be helpful in
other types of surgery.19 Swallowing is described as a
‘suboptimal activity’20 meaning that it can be adequate
for the purpose of obtaining oral nutrition even when
not at maximal physiological functioning. While it seems
intuitive that pretreatment swallowing exercises should
be helpful in increasing physiological reserve, reducing
disuse atrophy and possibly delaying the onset of
ﬁbrosis, uncertainty about its effectiveness in improving
swallowing for patients with HNC persists.21 Few rando-
mised clinical trials have attempted to address this
knowledge gap, with mixed results.17 22–28 Trials evaluat-
ing the effects of pretreatment swallowing exercises
suffer limitations in study design, and the lack of consist-
ent outcome measures across studies is problematic.21
Uncertainty also remains as to the optimal type and fre-
quency of exercises although such considerations are
less relevant to tailored interventions guided by prior
physiological assessment. The practice of providing
prophylactic swallowing exercises varies among UK clini-
cians,29 and to date there is no published UK data sup-
porting the effectiveness of pretreatment swallowing
exercise interventions in the HNC population.21 Any
pretreatment intervention package will need to address
often poor patient adherence to swallowing exer-
cises.22 24 30 Improved adherence may be achieved by
facilitating a change in patient behaviour. A new inter-
vention will also need to be compatible with the broader
cancer care pathway as detailed in ﬁgure 1.
Development of a tailored pretreatment swallowing
intervention package (SIP)
In preparation for the feasibility study described in this
manuscript, an optimised SIP was developed by the
researchers, guided by the methodology proposed by
the Medical Research Council (MRC) for devising
complex interventions incorporating multiple compo-
nents that may interact in producing outcomes.31 The
scope of the current work relates to the development
and feasibility testing phases of a complex intervention,
but the framework also includes evaluation and imple-
mentation phases with updated guidance that incorpo-
rates a process evaluation.32 We brieﬂy describe the
development work below.
Recognising the poor patient adherence reported in
previous studies of swallowing exercises,22 24 30 we paid
speciﬁc attention to optimising patient adherence
during the development phase by drawing on theoretical
frameworks and tools (The Behaviour Change Wheel,
Behaviour Change Technique Taxonomy v1) from the
ﬁeld of behavioural science.33 34
The new SIP—Swallowing Intervention Package: Self-
Monitoring, Assessment, Rehabilitation Training (SIP
SMART) was devised using current best evidence of swal-
lowing assessment,35 as well as insights from our earlier
studies exploring the behavioural dimensions of this
complex intervention; a systematic review of the litera-
ture36 and a patient interview study (submitted manuscript).
In our systematic review of behavioural swallowing
intervention studies,36 we used a published taxonomy
(BCTTv1)33 of 93 hierarchically organised behaviour
change techniques (BCTs), to identify the BCTs
reported in the literature. BCTs may be deﬁned as the
smallest active ingredient of an intervention that may
bring about a change in behaviour, for example, demon-
stration of the behaviour or self-monitoring of the behaviour.
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We surmised that the BCTs that were more frequently
associated with successful interventions were more likely
to be successful in future interventions.
We also carried out semistructured interviews with a
group of patients (n=13) who had completed treatment
for HNC to obtain their views and experiences of swallow-
ing rehabilitation exercises, and in addition obtained
feedback from respondents about the potential use of
video animations (Dysphagia App, Northern Speech
Services, USA) as an educational tool in explaining the
basic mechanics of swallowing. The barriers and facilita-
tors to exercise adherence revealed in our qualitative
study informed our behavioural analysis and the subse-
quent selection of BCTs for the SIP SMART intervention.
We ensured that the new SIP would meet mandatory
guidelines10 for information provision and informed
consent, and that it could feasibly be incorporated
within the existing cancer pathway for patients with
HNC. The new SIP was discussed and reﬁned by clin-
ician (Royal College of Speech and Language Therapist
expert clinician group (RCSLT)) and patient (patient–
public involvement group (PPI)) stakeholder groups.
Intervention manuals were produced for the new inter-
vention and usual care in collaboration with the stake-
holder groups. Figure 2 is a schematic diagram
illustrating an overview of this process and how it links
to the MRC complex interventions framework.
Although another complementary non-randomised
UK trial of pretreatment swallowing intervention
is planned,37 our SIP SMART trial is unique as it is
based on an optimised pretreatment intervention
using tailored exercises selected after physiological
assessment of swallowing, and is directly informed by
theoretically derived BCTs. Furthermore, comprehensive
evaluation of a new SIP is likely best performed using a
randomised controlled trial (RCT) design. Given the
uniqueness of our SIP and proposed future RCT evalu-
ation, a feasibility study was deemed imperative to ascer-
tain viability within a NHS context, and to identify and
address potential barriers to future roll out on a larger
scale.
In particular, the aims of this feasibility study are as
follows:
▸ Assess the rate of recruitment of eligible participants
and identify any speciﬁc barriers to recruitment.
▸ Determine the acceptability of randomisation, and
the randomisation procedure to patients and the clin-
ical care team.
▸ Determine retention and attrition over the time
course of the study.
▸ Evaluate the ease of protocol implementation, includ-
ing research processes, and identify barriers in the
clinical setting.
▸ Evaluate a range of potential outcome measures,
including the ease and completeness of data collec-
tion across various time points.
▸ Determine concordance between potential outcome
measures and deﬁne the most suitable primary
outcome for the deﬁnitive study.
▸ Collect data to inform future sample size calculation.
Figure 1 Pathway of care for patients with head and neck cancer.
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METHODS AND ANALYSIS
Study design
This study forms the preliminary testing phase described
within the MRC complex interventions framework.
Following on from our development work, we will conduct
a two-arm parallel group non-blinded randomised con-
trolled feasibility study. The SPIRIT38 (Standard Protocol
Items for Randomised Interventional Trials) checklist of
was used to inform the content of this protocol.
Study population, setting and recruitment plan
The study will take place at a single NHS hospital site
(Head and Neck Cancer Centre) with a catchment popula-
tion of 1.5 million. The study sample will be drawn from
the population of patients with newly diagnosed HNC
referred to the cancer centre, and discussed at the weekly
multidisciplinary team (MDT) meeting. Potential patients
for the study (based on diagnosis) will be identiﬁed during
the meeting by the researcher (RG), research nurse or
other members of the MDT. The research team will ensure
that the treating consultant is aware of potentially eligible
patients so that he/she may introduce the study during the
consultation with the patient if appropriate. For this feasi-
bility study, sample size was determined pragmatically using
the general guidance suggested by Lancaster and collea-
gues39 who recommend that n of 30 is sufﬁcient to estimate
key parameters in a feasibility study. Based on a conserva-
tive annual referral of ∼70 newly diagnosed stage III and
stage IV patients with HNC to the Head and Neck Centre,
we estimated that it will take about 9 months to recruit a
total of 32 patients to this study based on recruiting 60% of
eligible patients. Eligibility criteria for inclusion in the
study are listed in box 1.
Prescreening/screening
All patients who meet the clinical eligibility criteria iden-
tiﬁed at each MDT meeting will be recorded on the study
screening log by the researcher or research nurse.
Screening will take place at the outpatient clinic consult-
ation when treatment options are discussed by the
surgeon/oncologist. The researcher/clinician will attend
the consultations for eligible patients. If appropriate at
this stage, the purpose of the study will be explained and
patients will be given the patient information leaﬂet to
take away. Most patients will be booked for repeat visits to
the head and neck clinic prior to ﬁnalising their treat-
ment plan. Due consideration will be given to ensuring
that the study information is discussed at an appropriate
time after the diagnosis. Patients will be given a
minimum of 24 hours after receiving the patient informa-
tion sheet before a mutually agreed time is arranged to
Box 1 Inclusion and Exclusion Criteria
Inclusion:
▸ Patients with newly diagnosed stage III and stage IV head and
neck cancer.
▸ Discussed at the head and neck MDT and planned for treat-
ment via surgery and/or chemoradiotherapy or combinations
thereof.
▸ Able to provide informed consent.
▸ Proficiency in English satisfactory to participate/engage in the
intervention.
▸ Aged 18 and above.
Exclusion:
▸ Patients with previous head and neck cancer treatment.
▸ Patients who are mid treatment or those receiving palliation.
▸ Patients who are to be treated solely by non-standard treat-
ment that is not surgery, radiotherapy, chemoradiotherapy or
combinations thereof. Patients treated by chemotherapy,
brachytherapy and photodynamic therapy alone will be
ineligible.
▸ Patients who are planned for a total laryngectomy.
▸ Patients who are considered vulnerable or unable to provide
informed consent.
▸ Patients with brain tumours and other primary sites not within
head and neck.
Figure 2 Key stages of the *MRC complex interventions framework that informed the development and preliminary testing of
the SIP SMART intervention. *Source: Craig et al, BMJ;2008. MRC, Medical Research Council; SIP SMART, Swallowing
Intervention Package: Self-Monitoring, Assessment, Rehabilitation Training.
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answer any further questions to assist patients in deciding
about whether to participate. The time frame was chosen
because most patients return to the hospital for other
tests the day after their clinic visit. This offers an oppor-
tunity to answer questions in person and obtain signed
consent if appropriate. Patients will be reassured that par-
ticipation is voluntary with the freedom to withdraw at
any stage, and that participation in the study will not
affect or delay their main treatment.
Enrolment/consent
Informed consent will be obtained by the researcher/
clinician (RG) or a trained research nurse. Following
informed consent and generation of a patient study
identiﬁcation number, the patient will be entered onto
the study enrolment log and randomised to either the
SIP SMART intervention or usual care group as detailed
below.
Randomisation and allocation
Eligible patients will be randomly assigned in a 1:1 ratio
between usual care and intervention groups (ﬁgure 3
for trial ﬂow chart). Patients will be stratiﬁed by ﬁrst-line
treatment; surgery or chemoradiation, a known factor
that impacts swallowing outcomes.13 It will therefore be
necessary to ensure a balance of primary treatment
modality across the groups. Owing to the small numbers
in this study, random block permutations will be
employed to ensure a close match in numbers in the
intervention and usual care groups at any given point
during the trial.
Patients will be allocated to one of two groups using
an online computer-generated randomisation service
provided by an external company: http://www.
sealedenvelope.com/. The company is registered with
the Information Commissioners Ofﬁce (ICO) and
inspected by the MHRA (UK trials regulator). Following
consent, the researcher or research nurse will enter the
password-protected website and complete relevant infor-
mation regarding ﬁrst-line treatment. Randomisation is
immediate, and the group allocation is emailed within a
few minutes. This process is undertaken in the presence
of the patient after signed consent is obtained, ensuring
that the allocation is concealed until this point and sim-
ultaneously made known to the patient and researcher.
Allocation is not blinded as the patient and staff will be
aware that the new intervention includes a baseline
videoﬂuoroscopy or X-ray of swallowing. Patients allo-
cated to the usual care group are advised that they will
be sent an appointment in the post to see an SLT prior
to their treatment as per the usual care pathway. Patients
allocated to the intervention group are given an
appointment and a further information leaﬂet on
having a videoﬂuoroscopy to assess how well the muscles
and nerves function when swallowing different textures
of food and drink. All patients are given three question-
naires to complete and return prior to their appoint-
ment with the SLT.
Interventions and procedures
Usual care group: This group will receive the usual pre-
treatment care offered by the SLT prior to their upcom-
ing surgery and/or chemoradiation. The SLT clinical
team consisting of four members participated in a series
of consensus meetings regarding the delivery of usual
care to facilitate equipoise. All four team members
involved in the delivery of usual care have also under-
gone good clinical practice (GCP) training. A usual care
manual was written and agreed by the SLT clinical team
prior to initiation of the study to ensure a level of con-
sistency among the clinicians. Usual care pretreatment is
one 45 min consultation as described below:
▸ General case history taking and introduction of SLT
role.
▸ Clinical baseline screening of swallowing and commu-
nication function. This is usually based on an oro-
motor assessment; 100 mL water swallow test;40 a
clinician-rated Performance Status Scale indicating
the normalcy of diet texture and public eating
score;41 and a clinician-rated scale for chewing, com-
munication and swallowing.42 Maximal jaw opening
using a TheraBite measure and voice quality ratings
using the GRBAS (Grade of Hoarseness, Roughness,
Breathiness, Asthenia, Strain) rating scale are also
recorded.
▸ The patient is provided with a general overview of the
planned treatment (surgery or chemoradiation) and
information about the likely side effects such as
mucositis and taste changes and impact of treatment
on swallowing and communication function.
▸ General advice and exercises are offered to patients
planned for chemoradiation at this appointment.
Patients are provided with a general exercise sheet
that includes instructions for eight different swallow-
ing exercises, for example, passive jaw stretches. This
is included as part of the information pack given to
all patients receiving radiotherapy. Patients are
advised that it may be helpful to start doing the exer-
cises before treatment.
Intervention group: Patients in the intervention group
will be pretreated according to the SIP SMART protocol
that includes the speciﬁc components of the new inter-
vention in addition to all aspects of usual care. The
intervention takes place over two 45 min consultations
that may follow each other on the same day or with a
day or two between them depending on patient prefer-
ence. The new intervention will be delivered by one clin-
ician (RG) who completed a 5-day intensive training
course in behaviour change (UCL Centre for Behaviour
Change), supplemented by online training in coding
BCTs, as well as ongoing mentorship from an expert in
behaviour change. Speciﬁc details of the new interven-
tion have not been explicitly shared with clinicians deli-
vering usual care to minimise contamination. Broad
differences include the following:
▸ Patients will undergo a radiological assessment of
their swallow function in the ﬂuoroscopy suite at the
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hospital site. This procedure is part of the SIP
SMART intervention informing the selection of tar-
geted exercises, and is used as part of patient educa-
tion. A standard protocol for this clinical procedure
will be adopted for the study.35 The patient will be
asked to swallow a variety of food textures; ﬂuoro-
scopic images of the lateral and anterior–posterior
plane captured at a rate of 30 frames per second will
be recorded on a swallow workstation (Digital Kay
Pentax Swallow workstation, USA). This will be avail-
able for later analysis of swallow physiology. The ﬂuor-
oscopy screening time is usually 2–3 min.
▸ Patients will subsequently be shown a video animation
(Dysphagia App, Northern Speech Services, USA) to
Figure 3 Trial flow chart.
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explain the basic mechanics of swallowing and to
orientate them to key structures such as the tongue,
base of tongue, airway and oesophagus. Patients will
thereafter be shown their own videoﬂuoroscopy and
helped to identify the key structures using this newly
acquired knowledge. The clinician will encourage the
patient to provide commentary and or ask questions
as they watch their own swallowing.
▸ The videoﬂuoroscopy assessment will be used to
tailor the information, advice and exercises given to
the patient during the pretreatment session and to
facilitate discussion about the rationale for exercises
and possible consequences of not doing exercises.
▸ Further detail about the intervention content and
behavioural strategies used is provided in the SIP
SMART manual. This is not included in this paper,
but can be requested from the ﬁrst author.
Patients in both groups will follow the usual care
pathway for SLT rehabilitation post treatment (see ﬁgure 3
for trial ﬂow chart). The number of SLT rehabilitation ses-
sions for all patients will be recorded. Patients will be
informed that exercises may be amended post treatment
based on updated swallowing assessment.
Baseline and follow-up outcome measures
Swallowing is a multidimensional phenomenon that may
be measured by a number of different indicators including:
patient-reported outcome measures, clinician ratings and
scores from instrumental assessments such as videoﬂuoro-
scopy and ﬁbre-optic endoscopic evaluation of swallowing.
This range of outcomes can prove problematic when
synthesising ﬁndings from multiple studies. In this feasibil-
ity trial, we have selected a similar panel of swallowing
outcome measures to that used in concurrent UK trials for
HNC (radiation and surgery-based trials using a swallowing
outcome measure),43 as well as measures collected as part
of routine clinical practice (table 1). Outcome measures
will be collected at baseline and 1, 3 and 6 months after
treatment. Six months represents a relatively stable time
point in the recovery trajectory for patients with HNC and
was therefore selected as an appropriate end point.21 36
Patient weight, body mass index and use of feeding tube
will also be recorded at all time intervals. The MD
Anderson Dysphagia Inventory (MDADI)44 will be used to
determine swallowing related QOL. We have chosen to
collect information on health-related QOL via the
Functional Assessment of Cancer Therapy and Head and
Neck subscale (FACT-HN) as this questionnaire was identi-
ﬁed as the most preferred by patients with HNC when com-
pared with other QOL questionnaires.45
At 6 months, a videoﬂuoroscopy will be conducted on
all patients using the standardised Modiﬁed Barium
Swallow Impairment Proﬁle Protocol (MBS Imp Proﬁle),
and analysis.35 Three SLT clinicians who have completed
a 25 hour online training module and obtained the
minimum 80% reliability score will provide consensus
ratings for these assessments. Standard assessment rating
forms developed as part of the MBS Imp Proﬁle will be
used to score the videoﬂuoroscopies. We will also rate
aspiration from the videoﬂuoroscopies, based on the
widely used 8-point Penetration-Aspiration Scale (PAS).46
As we anticipate that adherence to swallowing exer-
cises should be associated with better swallowing, we will
also collect intermediate outcomes on adherence using
two simple questions developed for this trial. The ques-
tions will ask about percentage adherence over a speci-
ﬁed time, and a free text question to gather further
information about any speciﬁc reasons for adherence/
non-adherence to exercises.
Safety considerations
We do not anticipate any serious safety concerns arising
from this largely behavioural intervention. The use of
the videoﬂuoroscopy as part of the intervention is some-
times associated with aspiration of barium contrast
material but barium pneumonitis is reported to be rare
Table 1 Outcome measures and time points
Measure
T0
baseline
T1
1 month
T2
3 months
T3
6 months
Background information X
Measures taken as part of usual care
Performance Status Scale (PSS) X X X X
Maximal incisor opening (mouth opening) X X X X
Functional Intraoral Glasgow Scale X X X X
100 mL Water swallow test X X X X
Additional measures for trial
MD Anderson Dysphagia Inventory X X X X
General Self-Efficacy Scale X X
Self-reported adherence question X X X
HRQOL—FACT–HN X X X X
Modified Barium Swallow Impairment Score and
Penetration/Aspiration score
X
Acceptability to participation/randomisation questionnaire X
HRQOL—FACT–HN, Health Related Quality of Life- Functional Assessment of Cancer Treatment- Head & Neck subscale.
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at <1%.47 The additional radiation exposure associated
with the procedure is roughly the equivalent of
2 months of background radiation that an adult in the
UK may experience from the environment, and consid-
ered minor in the context of the patient’s overall treat-
ment. The procedure will be undertaken by an
experienced SLT familiar with the protocol for dealing
with an adverse event related to barium inhalation. The
procedure is also a well-established part of routine clin-
ical practice.
Data collection and management
We devised a number of study speciﬁc forms including a
case report form (CRF), screening log, enrolment log,
training log for any study-related training and ﬁle note
entry forms for any relevant ad hoc communication.
Patient names will be replaced by a study number on all
study forms and completion of CRFs will be in accord-
ance with GCP guidelines. A site ﬁle containing all rele-
vant documents as stipulated by local research and
development and governance guidelines will be main-
tained throughout the study and securely stored in a
locked cabinet. All patient-reported questionnaires will
also be securely ﬁled. Non-identiﬁable quantitative data
will be transferred from the questionnaires and CRFs to
a speciﬁcally designed Microsoft Access database by a
data manager. The database will ﬁrst be tested using
mock data to ensure that it meets the requirements for
data entry. A random check of ∼10% of the data input-
ted will be reviewed against the original source by the
researcher (RG) to estimate an error rate. This informa-
tion will help ensure that a robust data management
plan is in place for a more formal trial. The researcher
will maintain an electronic diary of relevant information
pertaining to the study processes on a password-
protected laptop computer.
Analysis
We will use mainly descriptive analysis and summary sta-
tistics to address our aims. Study screening and enrol-
ment logs will be used in determining the rate of
recruitment into the study. All qualitative information
(researcher diary), minutes of study-related discussions
and meetings will be imported into NVIVO 10, a soft-
ware database to facilitate the organisation and thematic
coding of qualitative or textual data. The researcher is
in a unique position of being embedded within the clin-
ical team, and therefore able to make observations over
the duration of the study in a naturalistic manner. This
approach to process analysis arguably may provide more
useful information than the use of post hoc focus
groups and interviews that rely on participant memory
and may be removed from context.48 Observing and col-
lecting information in this way also means that the
researcher can observe the interplay of other factors
(eg, multiple studies competing for the same patient
group, prevailing views of the treating consultant about
the value of the proposed intervention and how busy
the clinic is) that may reveal vital information about the
barriers and facilitators to recruitment.
We will also report on the practicality of implementing
the protocol, for example, obtaining timeslots for video-
ﬂuoroscopy; average time taken for the recruitment and
consent process; utility of the chosen randomisation
method and suitability of the study-speciﬁc forms includ-
ing the CRF. This information will be used to optimise
components of the protocol and study process in prepar-
ation for a larger trial.
As a range of outcome measures will be collected, we will
look at the suitability of each measure, the ease of collec-
tion and the quality and completeness of the data collec-
tion. We will observe the relationships (concordance and
discordance) between the different outcome measures to
help inform the most suitable choice of primary and sec-
ondary measures for a deﬁnitive trial. Important para-
meters such as SD and estimates of effect size will be used
to inform the sample size calculation. Based on the avail-
able literature, we will aim to specify the target difference
(clinically meaningful difference) for the chosen primary
outcome. The primary outcome measure will be chosen
from potential candidate measures on the basis that it is
valid, practical and feasible to obtain and has expert agree-
ment (RCSLT clinical expert group) that it reﬂects a good
summary measure to answer the question of whether the
new intervention is effective in improving swallowing.
Patient acceptability to participation and randomisa-
tion will be determined using a previously developed
questionnaire.49 Self-reported adherence to the inter-
vention will be explored via a brief study questionnaire.
Previous studies reported that full adherence to exer-
cises during radiotherapy was under 15%.27 30 In a
Danish study of a similar intervention to the current
study, an average of 35% of patients reported doing
their exercises at least once a day between 1 month and
11 months after treatment.22 We have therefore selected
35% as the minimum target adherence for our study.
Criteria for success
This study will be viewed as feasible to proceed to a
deﬁnitive trial if:
▸ a suitable outcome measure is determined, and
sample size estimated;
▸ recruitment rate into the trial reaches an average of
four patients a month;
▸ patients report generally positive views about partici-
pation and acceptance to randomisation as deter-
mined by questionnaire evaluation;
▸ patients in the intervention group are more adherent
than those in usual care, with at least 35% of inter-
vention group patients reporting satisfactory to good
adherence to exercises.
DISCUSSION
To the best of our knowledge, this is the ﬁrst rando-
mised UK study of a behavioural swallowing exercise
8 Govender R, et al. BMJ Open 2017;7:e014167. doi:10.1136/bmjopen-2016-014167
Open Access
group.bmj.com on May 23, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
intervention for patients with HNC registered on the
trials database. By undertaking a feasibility study and
identifying key uncertainties, any future study may be
optimised to make best use of resources.50 This study
follows earlier work on intervention development bring-
ing together expertise from different ﬁelds including
clinical dysphagia management and behaviour change.
It beneﬁts from the use of newer paradigms in health
research including the use of consultative and consensus
meetings to devise a treatment manual to specify the
content of usual care, a common omission when report-
ing such interventions.51 It is likely to provide a rich
source of information about how readily patients with a
new diagnosis of HNC will accept and participate in a
self-management-type intervention. It will also provide a
preliminary indication of the recruitment potential for
rehabilitation therapy trials for this population. A recent
UK study52 that randomised HNC patients to either a
pretreatment gastrostomy tube or a nasogastric tube
reported recruiting only 23% of eligible patients, high-
lighting the importance of this feasibility work. It is well
known that the treatment of HNC involves a complex
care pathway with multiple disciplines being involved,
particularly at the pretreatment stage. The feasibility of
undertaking a clinical trial at this point in the patient
pathway is compounded by the challenges of approach-
ing patients to participate in a trial shortly after receiving
a cancer diagnosis. Insights from this study may there-
fore have more widespread relevance for future studies
of this population.
Limitations of the study include the inability to blind
participants and staff to the randomisation allocation as all
patients in the intervention group will receive a video-
ﬂuoroscopy as part of the intervention. Based on the
limited number of individuals trained in rating videoﬂuor-
oscopies using the MBS impairment proﬁle, the same SLTs
involved in usual care delivery will be rating the assess-
ments. For this reason, we have chosen to use a consensus
rating from three clinicians as this method is likely to intro-
duce the least bias. We have not planned to evaluate ﬁdel-
ity in delivering the intervention at this stage, as only one
individual will be delivering the intervention (RG). In a
larger trial, training will be required by all clinicians
before delivering the intervention and ﬁdelity checks will
be built into the research process. In spite of these limita-
tions, the current study represents a ﬁrst and important
step towards examining the feasibility of undertaking a full-
scale RCTwithin NHS hospitals to determine the effective-
ness of a pretreatment swallowing intervention for patients
with HNC, delivered by SLTs.
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